Ianalumab for Lupus Nephritis

(SIRIUS-LN ext Trial)

This trial tests the safety and effectiveness of ianalumab for individuals with lupus nephritis, a kidney condition caused by lupus. It evaluates patient outcomes after stopping the treatment if they achieve certain improvements, or their response to ongoing treatment with ianalumab if they have not yet improved. Individuals who completed a previous related study and continue to experience issues with lupus nephritis might be suitable candidates for this trial. As a Phase 3 trial, this study represents the final step before FDA approval, offering participants the opportunity to contribute to the potential availability of a new treatment.

The trial information does not specify if you need to stop taking your current medications. However, it mentions that certain therapies are prohibited, so it's best to discuss your current medications with the trial team.

Research has shown that ianalumab is generally safe for people. In earlier studies involving patients with systemic lupus erythematosus (SLE), ianalumab was well-tolerated. No serious side effects were directly linked to the drug, and no patients discontinued participation because of it. Another study found that ianalumab was safe for patients with lupus nephritis, a condition where the immune system attacks the kidneys. The treatment was administered every four weeks, and participants were closely monitored for any side effects. Overall, these findings suggest that ianalumab is a safe treatment option for lupus-related conditions.¹²³⁴⁵

Ianalumab is unique because it targets a specific protein called BAFF-R, which plays a role in the survival and activity of B cells, a type of immune cell involved in lupus nephritis. Most standard treatments, like corticosteroids and immunosuppressants, work by broadly dampening the immune system. In contrast, Ianalumab offers a more targeted approach, potentially leading to fewer side effects and better efficacy. Researchers are excited because this precision targeting could provide a new level of relief for patients who do not respond well to existing therapies.

Studies have shown that ianalumab can effectively treat lupus nephritis. In earlier research, patients who took ianalumab experienced a 48.2% improvement in symptoms compared to those who took a placebo. This treatment targets B cells, a component of the immune system. Patients have tolerated ianalumab well, and it has achieved important goals in clinical studies. Early evidence suggests it may help reduce disease activity in lupus nephritis, making it a promising option for those affected by this condition. Depending on their response in the core study, participants in this trial will either discontinue study treatment while maintaining standard care medication or continue to receive open-label ianalumab.¹²⁴⁵⁶